Silence Therapeutics PLC

詳細情報 Silence Therapeutics PLC 企業名

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

企業情報

企業コードSLN

会社名Silence Therapeutics PLC

上場日Jan 05, 2010

最高経営責任者「CEO」Mr. Craig A. Tooman

従業員数116

証券種類Depository Receipt

決算期末Jan 05

本社所在地72 Hammersmith Road

都市LONDON

証券取引所NASDAQ Global Market Consolidated

国United Kingdom

郵便番号W14 8TH

電話番号442034576900

ウェブサイトhttps://www.silence-therapeutics.com/

企業コードSLN

上場日Jan 05, 2010

最高経営責任者「CEO」Mr. Craig A. Tooman

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

Ms. Gem Hopkins

Head of IR and Corporate Communications

--

Dr. Michael Harvey Davidson, M.D.

Non-Executive Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Timothy (Tim) McInerney

Independent Director

--

Mr. Craig A. Tooman

President, Chief Executive Officer, Executive Director

--

Dr. Steven J. Romano, M.D.

Executive Vice President, Chief of Research and Development Officer

--

Ms. Rhonda Heliums

Chief Financial Officer, Executive Vice President

--

Mr. Iain Gladstone Ross

Non-Executive Independent Chairman of the Board

--

Mr. David Jakob (Dave) Lemus, CPA

Non-Executive Independent Director

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q3

FY2023Q2

FY2023Q1

データなし

地域別USD

会社名

収益

比率

United Kingdom

43.11M

99.67%

Germany

144.00K

0.33%

USA

0.00

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

5.91%

Redmile Group, LLC

4.69%

Morgan Stanley & Co. LLC

4.01%

Other

54.59%

株主統計

比率

Griffiths (Richard Ian)

24.38%

TCG Crossover Management, LLC

6.42%

Invus Public Equities Advisors, LLC

5.91%

Redmile Group, LLC

4.69%

Morgan Stanley & Co. LLC

4.01%

Other

54.59%

種類

株主統計

比率

Individual Investor

24.38%

Investment Advisor

18.47%

Investment Advisor/Hedge Fund

10.53%

Hedge Fund

7.10%

Research Firm

5.08%

Venture Capital

3.35%

Private Equity

2.43%

Other

28.65%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

130

33.69M

71.34%

-14.09M

2025Q1

133

31.94M

67.63%

-14.00M

2024Q4

128

31.43M

66.56%

-10.23M

2024Q3

111

35.93M

77.05%

-5.19M

2024Q2

96

34.94M

74.95%

-4.57M

2024Q1

86

35.43M

76.18%

+4.14M

2023Q4

61

30.21M

78.15%

-609.51K

2023Q3

58

32.62M

88.08%

+1.55M

2023Q2

54

31.78M

89.08%

+2.79M

2023Q1

52

31.17M

88.54%

+2.74M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Griffiths (Richard Ian)

11.51M

24.38%

+543.58K

+4.95%

Jun 25, 2025

TCG Crossover Management, LLC

3.03M

6.42%

--

Mar 31, 2025

Invus Public Equities Advisors, LLC

2.79M

5.91%

-41.94K

-1.48%

Mar 31, 2025

Redmile Group, LLC

2.21M

4.69%

-184.37K

-7.68%

Mar 31, 2025

Morgan Stanley & Co. LLC

1.90M

4.01%

+333.48K

+21.34%

Mar 31, 2025

Lombard Odier Asset Management (USA) Corp.

1.85M

3.92%

-6.29K

-0.34%

Mar 31, 2025

Frazier Life Sciences Management, L.P.

1.15M

2.43%

--

Mar 31, 2025

Vivo Capital, LLC

1.11M

2.34%

--

Mar 31, 2025

Nantahala Capital Management, LLC

1.04M

2.21%

-7.25K

-0.69%

Mar 31, 2025

Nextech Invest, Ltd.

952.40K

2.02%

--

Mar 31, 2025

詳細を見る

5.920USD

Silence Therapeutics PLC

5.920

概要

企業名

金融